Skip to main content
Erschienen in: European Journal of Plastic Surgery 2/2023

29.09.2022 | Original Paper

Evaluating the effect of detection modalities in the Danish clinical follow-up program of cutaneous melanoma—a retrospective cohort study

verfasst von: Julie Tastesen Johannessen, Tue Duy Nguyen, Sarah Holmboe, Mikkel Børsen Rindom, Lars Bjørn Stolle

Erschienen in: European Journal of Plastic Surgery | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

A rising incidence of cutaneous melanoma causes a high prevalence of patients eligible for clinical follow-up, which increases the burden on the resources in the health care system. The objectives of this study are to investigate the effect of the current surveillance program in terms of detecting recurrence or development of de novo cutaneous melanomas and evaluate the efficacy of the different detection modalities including self-skin examination, physical examination, and routine imaging.

Methods

The study is designed as a retrospective cohort study. Patients with ≥ 1 follow-up visit(s) in the first 2 years after diagnosis of stage IB–IIIC disease in the melanoma surveillance program at Aarhus University Hospital in 2019 are included. Detection of recurrence rate by either physician-based examination, self-skin examination or routine imaging is compared.

Results

Two-hundred and ninety-one patients were included and 26 recurrences/de novo cutaneous melanomas were identified. Physician-based exams detected 39.5%, self-skin examination detected 34.9%, and imaging detected 27.8% of the recurrences.

Conclusions

Physician-based examination and self-skin examination are the most effective modalities to detect recurrences. Imaging modalities detected most recurrences when performed due to suspicion. The number needed to treat for stage IB was relatively high, which is why a prolonged interval between follow-up visits for this stage is advisable. The risk of recurrence is associated with disease stage which is why it is reasonable to base the follow-up program for melanoma patients on this parameter.
Level of evidence: Level II, Risk/Prognostic
Literatur
2.
Zurück zum Zitat Engholm G, Ferlay J, Christensen N et al (2019) NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9,1. [Internet]. NORDCAN; 2019. Tilgængelig hos: http://www.ancr.nu. Accessed 24 March 2022 Engholm G, Ferlay J, Christensen N et al (2019) NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9,1. [Internet]. NORDCAN; 2019. Tilgængelig hos: http://​www.​ancr.​nu. Accessed 24 March 2022
3.
Zurück zum Zitat Helvind NM, Hölmich LR, Smith S, Glud M, Andersen KK, Dalton SO (2015) Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24,059 melanoma cases. JAMA Dermatol 151(10):1087–95 CrossRefPubMed Helvind NM, Hölmich LR, Smith S, Glud M, Andersen KK, Dalton SO (2015) Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24,059 melanoma cases. JAMA Dermatol 151(10):1087–95 CrossRefPubMed
4.
Zurück zum Zitat Baade PD, Whiteman DC, Janda M, Cust AE, Neale RE, Smithers BM (2020) Long-term deaths from melanoma according to tumor thickness at diagnosis. Int J Cancer 147(5):1391–6CrossRefPubMed Baade PD, Whiteman DC, Janda M, Cust AE, Neale RE, Smithers BM (2020) Long-term deaths from melanoma according to tumor thickness at diagnosis. Int J Cancer 147(5):1391–6CrossRefPubMed
5.
6.
Zurück zum Zitat Barnhill RL, Fine JA, Roush GC, Berwick M (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78(3):427–32CrossRefPubMed Barnhill RL, Fine JA, Roush GC, Berwick M (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78(3):427–32CrossRefPubMed
7.
Zurück zum Zitat Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893–904CrossRefPubMed Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893–904CrossRefPubMed
8.
Zurück zum Zitat Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ (2000) Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7(2):87–97CrossRefPubMed Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ (2000) Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7(2):87–97CrossRefPubMed
9.
Zurück zum Zitat Retsas S, Henry K, Mohammed MQ, MacRae K (2002) Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer Oxf Engl 1990 38(4):511–6 Retsas S, Henry K, Mohammed MQ, MacRae K (2002) Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer Oxf Engl 1990 38(4):511–6
10.
Zurück zum Zitat Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45(12):3012–7CrossRefPubMed Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45(12):3012–7CrossRefPubMed
11.
Zurück zum Zitat Kim SH, Garcia C, Rodriguez J, Coit DG (1999) Prognosis of thick cutaneous melanoma. J Am Coll Surg marts 188(3):241–247CrossRef Kim SH, Garcia C, Rodriguez J, Coit DG (1999) Prognosis of thick cutaneous melanoma. J Am Coll Surg marts 188(3):241–247CrossRef
12.
Zurück zum Zitat Koskivuo I, Hernberg M, Vihinen P, Virolainen S, Talve L, Seppänen M (2011) Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg 98(10):1400–7CrossRefPubMed Koskivuo I, Hernberg M, Vihinen P, Virolainen S, Talve L, Seppänen M (2011) Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg 98(10):1400–7CrossRefPubMed
13.
14.
Zurück zum Zitat Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95(11):1401–7CrossRefPubMed Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95(11):1401–7CrossRefPubMed
16.
Zurück zum Zitat Deckers EA, Hoekstra-Weebers JEHM, Damude S, Francken AB, Ter Meulen S, Bastiaannet E (2020) The MELFO Study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients-results after 3 years. Ann Surg Oncol 27(5):1407–17CrossRefPubMed Deckers EA, Hoekstra-Weebers JEHM, Damude S, Francken AB, Ter Meulen S, Bastiaannet E (2020) The MELFO Study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients-results after 3 years. Ann Surg Oncol 27(5):1407–17CrossRefPubMed
17.
Zurück zum Zitat Read RL, Madronio CM, Cust AE, Goumas C, Watts CG, Menzies S (2018) Follow-up recommendations after diagnosis of primary cutaneous melanoma: a population-based study in New South Wales, Australia. Ann Surg Oncol 25(3):617–25CrossRefPubMed Read RL, Madronio CM, Cust AE, Goumas C, Watts CG, Menzies S (2018) Follow-up recommendations after diagnosis of primary cutaneous melanoma: a population-based study in New South Wales, Australia. Ann Surg Oncol 25(3):617–25CrossRefPubMed
18.
Zurück zum Zitat Shirai K, Wong SL (2018) Melanoma surveillance strategies: different approaches to a shared goal. Ann Surg Oncol marts 25(3):583–584CrossRef Shirai K, Wong SL (2018) Melanoma surveillance strategies: different approaches to a shared goal. Ann Surg Oncol marts 25(3):583–584CrossRef
19.
Zurück zum Zitat Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A (2012) Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 22(5):376–85CrossRefPubMed Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A (2012) Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 22(5):376–85CrossRefPubMed
20.
Zurück zum Zitat Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208CrossRefPubMedPubMedCentral Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMed Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381CrossRefPubMed
22.
Zurück zum Zitat Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW (2002) Nodular type and older age as the most significant associations of thick melanoma in Victoria. Australia Arch Dermatol maj 138(5):609–614 Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW (2002) Nodular type and older age as the most significant associations of thick melanoma in Victoria. Australia Arch Dermatol maj 138(5):609–614
23.
Zurück zum Zitat Herbert A, Koo MM, Barclay ME, Greenberg DC, Abel GA, Levell NJ (2020) Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data. Melanoma Res 30(3):279–85CrossRefPubMed Herbert A, Koo MM, Barclay ME, Greenberg DC, Abel GA, Levell NJ (2020) Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data. Melanoma Res 30(3):279–85CrossRefPubMed
24.
Zurück zum Zitat Tjokrowidjaja A, Browne L, Soudy H (2021) External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.13689 Tjokrowidjaja A, Browne L, Soudy H (2021) External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. Asia Pac J Clin Oncol. https://​doi.​org/​10.​1111/​ajco.​13689
25.
Zurück zum Zitat Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA (2020) Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol 122(8):1770–7CrossRefPubMed Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA (2020) Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol 122(8):1770–7CrossRefPubMed
26.
Zurück zum Zitat Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K (2017) Patient symptoms are the most frequent indicators of recurrence in patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg 224(4):652–9CrossRefPubMed Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K (2017) Patient symptoms are the most frequent indicators of recurrence in patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg 224(4):652–9CrossRefPubMed
27.
Zurück zum Zitat Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS (2017) Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol 24(4):939–46CrossRefPubMed Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS (2017) Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol 24(4):939–46CrossRefPubMed
28.
Zurück zum Zitat Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL (1999) Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11):2252–8CrossRefPubMed Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL (1999) Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11):2252–8CrossRefPubMed
29.
Zurück zum Zitat Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD (2009) Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 16(4):941–7CrossRefPubMed Meyers MO, Yeh JJ, Frank J, Long P, Deal AM, Amos KD (2009) Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol 16(4):941–7CrossRefPubMed
30.
Zurück zum Zitat Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF (2017) Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. J Clin Oncol Off J Am Soc Clin Oncol 35(15):1721–9CrossRef Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF (2017) Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. J Clin Oncol Off J Am Soc Clin Oncol 35(15):1721–9CrossRef
31.
Zurück zum Zitat Weinstock MA, Risica PM, Martin RA, Rakowski W, Dubé C, Berwick M (2007) Melanoma early detection with thorough skin self-examination: the “Check It Out” randomized trial. Am J Prev Med 32(6):517–24CrossRefPubMedPubMedCentral Weinstock MA, Risica PM, Martin RA, Rakowski W, Dubé C, Berwick M (2007) Melanoma early detection with thorough skin self-examination: the “Check It Out” randomized trial. Am J Prev Med 32(6):517–24CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C (2005) Sun exposure and mortality from melanoma. J Natl Cancer Inst 97(3):195–9CrossRefPubMed Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C (2005) Sun exposure and mortality from melanoma. J Natl Cancer Inst 97(3):195–9CrossRefPubMed
33.
Zurück zum Zitat Manne S, Lessin S (2006) Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors. J Behav Med oktober 29(5):419–434CrossRef Manne S, Lessin S (2006) Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors. J Behav Med oktober 29(5):419–434CrossRef
34.
Zurück zum Zitat Weinstock MA, Risica PM, Martin RA, Rakowski W, Smith KJ, Berwick M (2004) Reliability of assessment and circumstances of performance of thorough skin self-examination for the early detection of melanoma in the Check-It-Out Project. Prev Med 38(6):761–5CrossRefPubMed Weinstock MA, Risica PM, Martin RA, Rakowski W, Smith KJ, Berwick M (2004) Reliability of assessment and circumstances of performance of thorough skin self-examination for the early detection of melanoma in the Check-It-Out Project. Prev Med 38(6):761–5CrossRefPubMed
35.
Zurück zum Zitat Robinson JK, Rigel DS, Amonette RA (1998) What promotes skin self-examination? J Am Acad Dermatol maj 38(5 Pt 1):752–757CrossRef Robinson JK, Rigel DS, Amonette RA (1998) What promotes skin self-examination? J Am Acad Dermatol maj 38(5 Pt 1):752–757CrossRef
36.
Zurück zum Zitat Xing Y, Cromwell KD, Cormier JN (2012) Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract 2012:1–4CrossRef Xing Y, Cromwell KD, Cormier JN (2012) Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract 2012:1–4CrossRef
37.
Zurück zum Zitat Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE (2014) Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 259(6):1215–22CrossRefPubMed Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE (2014) Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg 259(6):1215–22CrossRefPubMed
38.
Zurück zum Zitat Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D (2002) Primary staging and follow-up in melanoma patients–monocenter evaluation of methods, costs and patient survival. Br J Cancer 87(2):151–7CrossRefPubMedPubMedCentral Hofmann U, Szedlak M, Rittgen W, Jung EG, Schadendorf D (2002) Primary staging and follow-up in melanoma patients–monocenter evaluation of methods, costs and patient survival. Br J Cancer 87(2):151–7CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Helvind NM, Aros Mardones CA, Hölmich LR, Hendel HW, Bidstrup PE, Sørensen JA (2021) Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 47(12):3020–7 Helvind NM, Aros Mardones CA, Hölmich LR, Hendel HW, Bidstrup PE, Sørensen JA (2021) Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 47(12):3020–7
41.
Zurück zum Zitat Pellacani G, Farnetani F, Chester J, Kaleci S, Ciardo S, Bassoli S (2022) Cutaneous melanoma systematic diagnostic workflows and integrated reflectance confocal microscopy assessed with a retrospective, comparative longitudinal (2009–2018) study. Cancers 14(3):838CrossRefPubMedPubMedCentral Pellacani G, Farnetani F, Chester J, Kaleci S, Ciardo S, Bassoli S (2022) Cutaneous melanoma systematic diagnostic workflows and integrated reflectance confocal microscopy assessed with a retrospective, comparative longitudinal (2009–2018) study. Cancers 14(3):838CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Longo C, Moscarella E, Pepe P, Cesinaro AM, Casari A, Manfredini M (2011) Confocal microscopy of recurrent naevi and recurrent melanomas: a retrospective morphological study: RCM of recurrent naevi and melanoma. Br J Dermatol 165(1):61–8CrossRefPubMed Longo C, Moscarella E, Pepe P, Cesinaro AM, Casari A, Manfredini M (2011) Confocal microscopy of recurrent naevi and recurrent melanomas: a retrospective morphological study: RCM of recurrent naevi and melanoma. Br J Dermatol 165(1):61–8CrossRefPubMed
43.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol Off J Am Soc Clin Oncol 19(16):3622–34CrossRef Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol Off J Am Soc Clin Oncol 19(16):3622–34CrossRef
44.
Zurück zum Zitat Donizy P, Kaczorowski M, Leskiewicz M, Zietek M, Pieniazek M, Kozyra C (2014) Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Oncol Rep 32(6):2735–43CrossRefPubMed Donizy P, Kaczorowski M, Leskiewicz M, Zietek M, Pieniazek M, Kozyra C (2014) Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. Oncol Rep 32(6):2735–43CrossRefPubMed
Metadaten
Titel
Evaluating the effect of detection modalities in the Danish clinical follow-up program of cutaneous melanoma—a retrospective cohort study
verfasst von
Julie Tastesen Johannessen
Tue Duy Nguyen
Sarah Holmboe
Mikkel Børsen Rindom
Lars Bjørn Stolle
Publikationsdatum
29.09.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Plastic Surgery / Ausgabe 2/2023
Print ISSN: 0930-343X
Elektronische ISSN: 1435-0130
DOI
https://doi.org/10.1007/s00238-022-01997-4

Weitere Artikel der Ausgabe 2/2023

European Journal of Plastic Surgery 2/2023 Zur Ausgabe

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.